Interview with John Montgomery , CEO, Alphapharm
Alphapharm recently celebrated its 25th anniversary. In light of this significant milestone, would you give us a brief introduction to the company? Alphapharm started in 1982 in Brisbane with a…
Address: PO Box 196 Hawthorn Victoria 3122
Tel: (03) 8823 7333
Web: http://www.servier.com.au/home/default.asp
In just over 20 years, turnover has increased from $1 million in 1984 to $107 million for 2009. The number of people employed has risen steadily. The Sales force has grown from 6 representatives in 1984 spread across all Australian regions to in excess of 120 representatives today, but has maintained its reputation throughout this time as being amongst one of the best trained, most professional and most productive in Australia.
Servier’s activities in Australia commenced in 1979 with the launch of the anti-diabetic agent- Diamicron
Pivotal development work for the group’s flagship product Coversyl, which led to more than 30 publications from Australian researchers prior to marketing approval, culminated with the launch of Coversyl 2mg and 4mg in 1992.
In 1999 The International Centre for Therapeutic Research was established in Australia- The first outside of Europe and now has a staff in excess of 30 involved in phase l,ll and lll clinical research.
By January 1999 the company had outgrown it’s head office of 15 years and moved to it’s new purpose built office in Hawthorn, Melbourne, which saw the divisions of Sales/Marketing and Research all housed under the one roof.
Coversyl 8mg was launched in February 2004 and already contributes 21% of the Company annual turnover.
Coralan, a new treatment for chronic stable angina was registered in November 2006.
In April 2007, Protos, a new treatment for post menopausal osteoporosis was listed on the PBS.
Servier Australia is the local subsidiary of Servier, a leading French research-based pharmaceutical entity, specialising in ethical pharmaceuticals. Employing over 200 people in Australia, its headquarters are in Hawthorn, Melbourne. In 2009 Servier Australia had an annual turnover of $107 million.
Servier Laboratories Limited comprises two principal divisions:
Clinical Research
The management of phase l, ll, lll and lV clinical trials in collaboration with research-based hospitals and general practices throughout Australia.
Sales and Marketing
Sales and Marketing deliver Servier’s portfolio of ethical pharmaceutical products to primary and secondary healthcare professionals
In addition to a team of representatives throughout Australia, to support the operational activities of the above divisions, there is naturally a complete range of professional support functions that include the following: Training, Medical Information (Marketing), Regulatory Affairs, Human Resources, Finance, Information Services, Strategic Coordination, External and Government Relations and Medical Affairs.
Servier Australia offers a range of products in a number of medical areas: cardiovascular disease, especially hypertension and cardiac disease, diabetes and more recently osteoporosis
Alphapharm recently celebrated its 25th anniversary. In light of this significant milestone, would you give us a brief introduction to the company? Alphapharm started in 1982 in Brisbane with a…
What impact have the PBS reforms had on sanofi-aventis in Australia? Sanofi-aventis has one of the largest portfolios of medicines in Australia, with over 240 products in the key areas…
Would you please introduce Pretium’s specific service offerings, and the focus within these? Pretium offers a comprehensive range of integrated services across our 4 lines of business – Market Intelligence,…
One of the hot topics in the industry is the impact of PBS reforms. Can you speak to recent influence of PBS reforms affecting Novotech’s services in Australia? In our…
Would you please introduce Pierre Fabre to our readers? Pierre Fabre Medicament Australia Pty Limited was established in Australia in late 2001, and is a fully owned subsidiary of the…
The Australian pharmaceutical sector has seen recent innovations through PBS reform and various working groups shaping the future of the industry. Can you comment on how Datapharm is reacting to…
What impact will the recent PBS reforms have on Genzyme’s operations in Australia? Genzyme is different in terms of its focus on rare & unmet medical needs, so most of…
To begin, would you please introduce Medicines Australia to Pharmaceutical Executive readers? Medicines Australia is the national industry association for innovative pharmaceutical companies. . Just about every company engaged in…
What impact have the PBS reforms had on Nycomed? As most mid size Pharma companies that operate in a setting of mass market prescription medicines, Nycomed is also experiencing the…
New Government health priorities and policies, highlighting those concerning preventive health. The Rudd Labor Government’s goal in health is to create a modern health system designed for the health needs…
How have your experiences at Quintiles, Astra, Baxter, and Innovex – covering the spectrum from small to large pharma in addition to the service side – helped in managing IMS…
Pharmacor is one of the newest entities on the Australian pharmaceutical market. Would you please introduce the company to let Pharmaceutical Executive readers understand more about the Pharmacor story? Pharmacare…
See our Cookie Privacy Policy Here